Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam

Journal of Clinical Pharmacology

Volumn 37, Issue 5, 1997, Pages 442-450

  Samara, Emil E ^a   Granneman, Richard G ^a   Witt, Galen F ^a   Cavanaugh, John H ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORAZEPAM; PLACEBO; VALPROATE SEMISODIUM;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG SAFETY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; TINNITUS; VERTIGO; VOMITING;

EID: 0030959978     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04322.x     Document Type: Review

References (15)

1. McElroy SL, Keck PE, Pope HG, Hudson JI: Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989;50(suppl 3):23-29.
2. Fawcett J: Valproate use in acute mania and bipolar disorder: an international perspective. J Clin Psychiatry 1989;50(suppl 3):10-12.
3. Pope HG, McElroy SL, Keck PE, Hudson JI: Valproate in the treatment of acute mania. Arch Gen Psychiatry 1991;48:62-68.
4. Bowden Cl, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al: Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1984;271:918-924.
5. Anderson GD, Gidal BE, Kantor ED, Wilenskv AJ: Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. Epilepsia 1994;35:221-225.
6. Yuen AWC, Land G, Weatherley BC, Peck AW: Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;35:511-513.
7. Lertora JJ, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE, Agrawal CK: Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1994;56:272-278.
8. Greenblatt DJ, Franke K, Shader RI: Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography. J Chromatogr 1978;146:311-320.
9. Gibaldi M, Perrier D: Pharmacokinetics. Second Edition. New York: Marcel Dekker, 1982.
10. Locke CS: An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984;12:649-655.
11. Fieller E: Some problems in interval estimation. J R Stat Soc Ser B 1954;16:175-185.
12. Chun AHC, Lamm JE, Witt GF, Cavanaugh JH: Multiple dose evaluation of the absorption characteristics of divalproex sodium tablets, a delayed-release preparation of valproate in healthy volunteers. Clin Drug Invest 1995;10:40-47.
13. Gilman GA, Rall TW, Nies AS, Taylor P: Goodman and Gilman 's The Pharmacological Basis of Therapeutics. Eighth Edition. New York: McGraw-Hill, 1990.
14. Anderson GD, Levy RH: The effect of valproate on the metabolism of phenobarbital in the rat. Pharm Res 1992;9:1622-1628.
15. Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI: Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 1988;44:326-334.